Literature DB >> 30819473

Nomogram and Artificial Neural Network for Prognostic Performance on the Albumin-Bilirubin Grade for Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.

Bin-Yan Zhong1, Cai-Fang Ni2, Jian-Song Ji3, Guo-Wen Yin4, Li Chen1, Hai-Dong Zhu1, Jin-He Guo1, Shi-Cheng He1, Gang Deng1, Qi Zhang1, Pei-Cheng Li2, Hui Yu4, Jing-Jing Song3, Gao-Jun Teng5.   

Abstract

PURPOSE: To construct the albumin-bilirubin (ALBI) grade and the Child-Turcotte-Pugh (CTP) score based on nomograms, as well as to develop an artificial neural network (ANN) to compare the prognostic performance of the 2 scores for hepatocellular carcinoma (HCC) that has undergone transarterial chemoembolization.
MATERIALS AND METHODS: This multicentric retrospective study included patients with HCC who underwent transarterial chemoembolization monotherapy as an initial treatment at 4 institutions between January 2008 and December 2016. In the training cohort, significant risk factors associated with overall survival (OS) were identified by univariate and multivariate analyses. The prognostic nomograms and ANN were established and then validated in 2 validation cohorts.
RESULTS: A total of 838 patients (548, 115, and 175 in the training cohort and validation cohorts 1 and 2, respectively) were included. The median OS was 10.4, 15.7, and 9.2 months in the training cohort and validation cohorts 1 and 2, respectively. In the training cohort, both ALBI grade and CTP score were identified as significant risk factors. The ALBI grade and CTP score based on nomograms were established separately and showed similar prognostic performance when assessed externally in validation cohorts (C-index in validation cohort 1: 0.823 vs 0.802, P = .417; in validation cohort 2: 0.716 vs 0.729, P = .793). ANN showed that ALBI grade had higher importance on survival prediction than CTP score.
CONCLUSIONS: ALBI grade performs at least no worse than CTP score regarding survival prediction for HCC receiving transarterial chemoembolization. Considering the easy application, ALBI grade has the potential to be regarded as an alternative to CTP score.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30819473     DOI: 10.1016/j.jvir.2018.08.026

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  10 in total

1.  Preoperative estimation of the survival of patients with unresectable hepatocellular carcinoma achieving complete response after conventional transcatheter arterial chemoembolization: assessments of clinical and LI-RADS MR features.

Authors:  Wenlong Song; Qianyu Chen; Dajing Guo; Caiming Jiang
Journal:  Radiol Med       Date:  2022-08-26       Impact factor: 6.313

Review 2.  Artificial Intelligence in Interventional Radiology.

Authors:  Joseph R Kallini; John M Moriarty
Journal:  Semin Intervent Radiol       Date:  2022-08-31       Impact factor: 1.780

Review 3.  Role of three-dimensional printing and artificial intelligence in the management of hepatocellular carcinoma: Challenges and opportunities.

Authors:  Chrysanthos D Christou; Georgios Tsoulfas
Journal:  World J Gastrointest Oncol       Date:  2022-04-15

4.  Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study.

Authors:  Lei Zhang; Jun-Hui Sun; Zhong-Heng Hou; Bin-Yan Zhong; Zhi-Ping Yan; Cai-Fang Ni; Min-Jie Yang; Guan-Hui Zhou; Wan-Sheng Wang; Peng Huang; Shen Zhang; Zhi Li; Xiao-Li Zhu
Journal:  Cardiovasc Intervent Radiol       Date:  2020-09-23       Impact factor: 2.740

Review 5.  Interventional Radiology ex-machina: impact of Artificial Intelligence on practice.

Authors:  Martina Gurgitano; Salvatore Alessio Angileri; Giovanni Maria Rodà; Alessandro Liguori; Marco Pandolfi; Anna Maria Ierardi; Bradford J Wood; Gianpaolo Carrafiello
Journal:  Radiol Med       Date:  2021-04-16       Impact factor: 3.469

6.  Prognostic Performance of Albumin-Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib.

Authors:  Bin-Yan Zhong; Zhi-Ping Yan; Jun-Hui Sun; Lei Zhang; Zhong-Heng Hou; Min-Jie Yang; Guan-Hui Zhou; Wan-Sheng Wang; Zhi Li; Peng Huang; Shen Zhang; Xiao-Li Zhu; Cai-Fang Ni
Journal:  Front Oncol       Date:  2020-12-18       Impact factor: 6.244

7.  Predicting the Initial Treatment Response to Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma by the Integration of Radiomics and Deep Learning.

Authors:  Jie Peng; Jinhua Huang; Guijia Huang; Jing Zhang
Journal:  Front Oncol       Date:  2021-10-21       Impact factor: 6.244

Review 8.  The ALBI score: From liver function in patients with HCC to a general measure of liver function.

Authors:  Hidenori Toyoda; Philip J Johnson
Journal:  JHEP Rep       Date:  2022-08-18

9.  A novel diagnostic four-gene signature for hepatocellular carcinoma based on artificial neural network: Development, validation, and drug screening.

Authors:  Min Chen; Guang-Bo Wu; Zhi-Wen Xie; Dan-Li Shi; Meng Luo
Journal:  Front Genet       Date:  2022-09-28       Impact factor: 4.772

10.  Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review.

Authors:  Ayman Bannaga; Ramesh P Arasaradnam
Journal:  World J Gastroenterol       Date:  2020-09-07       Impact factor: 5.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.